LP-935509

Category	SARS-CoV
CAS	1454555-29-3
Description	LP-935509 is a brain penetrant inhibitor of adapter protein-2 associated kinase 1 (AAK1; IC50 value 3.3 nM and 14 nM and 320 nM for the closely related BIKE and GAK enzymes, repsectively). LP-935509 exhibits antinociceptive property in multiple rat models of neuropathic pain, but not acute pain. The antinociception of AAK1 inhibitor can be blocked by α2 adrenergic antagonists.

Quotation Now

Synonyms	LP935509; LP 935509; LP-935509; Isopropyl 4-(3-(2-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine-1-carboxylate; 4-[3-(2-Methoxy-pyridin-3-yl)-pyrazolo[1,5-a]pyrimidin-5-yl]-piperazine-1-carboxylic acid isopropyl ester
Molecular Weight	396.44
Molecular Formula	C20H24N6O3
Canonical SMILES	CC(C)OC(=O)N1CCN(CC1)C2=NC3=C(C=NN3C=C2)C4=C(N=CC=C4)OC
InChI	InChI=1S/C20H24N6O3/c1-14(2)29-20(27)25-11-9-24(10-12-25)17-6-8-26-18(23-17)16(13-22-26)15-5-4-7-21-19(15)28-3/h4-8,13-14H,9-12H2,1-3H3
InChIKey	GOOYSJIWTIHOGW-UHFFFAOYSA-N
Purity	99%
Solubility	In vitro: 10 mM in DMSO
Appearance	Light yellow to yellow (Solid)
Application	antinociceptive agent
Storage	Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month
Complexity	556
Exact Mass	396.19098865
In Vitro	LP-935509 inhibits μ2 phosphorylation with an IC50 value of 2.8 ± 0.4 nM, inhibits phosphorylation of a peptide derived from the μ2 protein with an IC50 value of 3.3 ± 0.7 nM. LP-935509 exhibits a dose-dependent inhibition of the SARS-CoV-2 S-RBD internalization into host cells.
In Vivo	LP-935509 (0-60 mg/kg; PO, single) causes a robust reduction in pain behavior. LP-935509 (0.1-30 mg/kg; PO, single dosage) causes a dose-dependent reversal of thermal hyperalgesia in CCI model. LP-935509 (IV (1 mg/kg) or orally (10 mg/kg); once) has 100% oral bioavailability and a plasma half life of 3.6 hours.
Target	AAK1; Cyclin G-associated Kinase (GAK); SARS-CoV
XLogP3-AA	2.1